skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

In the developing pharma landscape, it’s important to consider all variables to create a winning portfolio strategy. To support the development of your own successful portfolio strategy, Pharma Intelligence invites you to watch our webinar: “Where is the pharma industry maximizing value?”, filmed on Tuesday May 23, 2017, presented by Datamonitor Healthcare Principal Analyst, Amanda Micklus.

 

This webinar focuses on the state of the pharma industry regarding long-term portfolio planning from the R&D stage through externalization and commercialization. Covered topics include:

 

Business development trends, including - internal R&D spending (including productivity measurements). What are the factors contributing to the projected sharp CAGR decline through 2020? Who shows most success with new product launches, and why?

 

Licensing and deal-making - How does pharma complement internal R&D with external business development deals? Find out by volume, value, phase, and therapy area.

 

Revenue trends – How do we view R&D investment and licensing/deal-making through the lens of revenue? Compare companies in Big Pharma, Mid Pharma, and Japan Pharma in terms of internal R&D product revenue versus that from external products.

 

Read also

  • Datamonitor Healthcare: data analysis and insight

    Pharma Must Not Let Its COVID-19 Halo Slip

    By Daniel Chancellor

    Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination.

    Topics Coronavirus $name BioPharmaceutical

  • Datamonitor Healthcare: data analysis and insight, Pink Shee...

    Pharma Intelligence Podcasts

    Listen to the Pharma Intelligence podcasts on Spotify, Apple Podcasts, Soundcloud and Alexa

    Topics Coronavirus $name $name Clinical Trials Blog Clinical Trials Drug Pricing

  • Datamonitor Healthcare: data analysis and insight

    mHealth and Research in Oncology

    The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit. 

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: